At the beginning of the COVID-19 pandemic, patients with immune-mediated inflammatory
diseases were considered to be at high risk for SARS-CoV-2 infection and the development …

As the world navigates the coronavirus disease 2019 (COVID-19) pandemic, there is a
growing need to assess its impact in patients with autoimmune rheumatic diseases, such as …

Objective To provide guidance to rheumatology providers on the use of coronavirus disease
2019 (COVID‐19) vaccines for patients with rheumatic and musculoskeletal diseases …

Objectives As global vaccination campaigns against COVID-19 disease commence, vaccine
safety needs to be closely assessed. The safety profile of mRNA-based vaccines in patients …

Patients with rheumatic diseases are at increased risk of infectious complications;
vaccinations are a critical component of their care. Disease-modifying antirheumatic drugs …

Vaccines represent one of the most effective measures of public health medicine, saving
countless lives and preventing lifelong disabilities. Vaccines are extremely safe, however …

Aim To present a systematic literature review (SLR) on efficacy, immunogenicity and safety
of vaccination in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD) …

Objective Patients with autoimmune inflammatory rheumatic diseases receiving rituximab
(RTX) therapy are at higher risk of poor COVID‐19 outcomes and show substantially …

Objectives Successful vaccination is key to overcoming the COVID-19 pandemic.
Immunosuppressive medication is known to potentially compromise vaccination responses …

Objective To provide guidance to rheumatology providers on the use of COVID‐19 vaccines
for patients with rheumatic and musculoskeletal diseases (RMDs). Methods A task force was …